
    
      The purpose of this study is to evaluate the overall COPD patient experience with the
      Nuvairaâ„¢ Lung Denervation System and allow for the continued collection of safety and
      effectiveness data on the CE-marked product. The study is a multicenter, prospective,
      single-arm study designed to include patients, on average, who fall within a more severe
      stage of COPD, defined as 20-45% FEV1 percent predicted. Subjects will remain on respiratory
      medications per their standard of care and will be followed and tested per standard of care
      throughout the study.
    
  